43 completed. 43 Phase 2, 5 Phase 1, 5 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 43 | Completed 43 |
| Phase 1 | 5 | Completed 5 |
| Phase 3 | 5 | Completed 5 |
Follow Obstructive Sleep Apnea: new trials by email Literature Review of Obstructive Sleep Apnea trials Research Report on Obstructive Sleep Apnea
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Assess the Efficacy and Safety of Lorundrostat in Participants With Obstructive Sleep Apnea and Hypertension Lorundrostat, Placebo - Obstructive Sleep Apnea, Hypertension | Phase 2 | Completed | Mineralys Therapeutics Inc. | 48 | 2025-02-28 | 2026-08-21 |
| RePOSA-Revealing the Efficacy of IHL-42X Use in Patients With OSA IHL-42X Low Dose, IHL-42X High Dose, Placebo - Obstructive Sleep Apnea | Phase 2 / Phase 3 | Completed | Incannex Healthcare Ltd | 121 | 2024-05-02 | 2026-07-27 |
| Managing Opioid Related Sleep Apnea With Acetazolamide Acetazolamide, Placebo - Sleep-Disordered Breathing, Obstructive Sleep Apnea | Phase 2 | Completed | University of California, San Diego | 39 | 2023-10-18 | 2026-03-10 |
| Endotype-Targeted Therapy to Rescue OSA Patients Struggling With CPAP Adherence (TOP-CPAP) Eszopiclone 2 mg, Placebo - Obstructive Sleep Apnea | Phase 2 | Completed | University of California, San Diego | 42 | 2023-08-31 | 2025-11-25 |
| AD816 Crossover Study Period A, Period B, Period C - OSA, Obstructive Sleep Apnea | Phase 2 | Completed | Apnimed | 25 | 2023-04-28 | 2023-11-15 |
| Acetazolamide on REM OSA Placebo oral capsule, Acetazolamide - Obstructive Sleep Apnea | Phase 1 / Phase 2 | Completed | Brigham and Women's Hospital | 11 | 2023-01-30 | 2026-01-20 |
| Acetazolamide for Obstructive Sleep Apnea to Improve Heart Health Acetazolamide, Placebo, Continuous Positive Airway Pressure - Obstructive Sleep Apnea | Phase 2 | Completed | University of California, San Diego | 54 | 2022-12-02 | 2025-11-25 |
| Pediatric Pain Optimization After Tonsillectomy Fentanyl/Hydromorphone, Methadone - Obstructive Sleep Apnea, Tonsillitis | Phase 2 | Completed | Duke University | 66 | 2022-04-08 | 2024-10-17 |
| Efficacy, Safety and Tolerability of Sulthiame in Patients With Obstructive Sleep Apnea (OSA) Sulthiame - Obstructive Sleep Apnea | Phase 2 | Completed | Desitin Arzneimittel GmbH | 298 | 2021-11-23 | 2023-11-29 |
| Study for Efficacy and Dose Escalation of AD313 + Atomoxetine (SEED) Dosing 1: Atomoxetine, AD313 - Obstructive Sleep Apnea | Phase 1 / Phase 2 | Completed | Apnimed | 15 | 2021-10-19 | 2023-04-07 |
| Prospective Randomized Trial of CPAP for SDB in Patients Who Use Opioids Positive Airway Pressure (PAP) - Sleep Disorder; Breathing-Related, Pain | Phase 2 | Completed | University of California, San Diego | 62 | 2021-08-10 | 2024-12-02 |
| Trial of AD113 and Atomoxetine in OSA Patients With Hypertension AD113, Atomoxetine - Obstructive Sleep Apnea, Hypertension | Phase 2 | Completed | Apnimed | 21 | 2021-07-31 | 2023-08-21 |
| AD109 Dose Finding in Mild to Moderate OSA AD109 dose1- A, AD109 dose2- B, Placebo- C - Obstructive Sleep Apnea | Phase 2 | Completed | Apnimed | 32 | 2020-12-22 | 2022-12-22 |
| Crossover Trial of AD182 and AD504 in Obstructive Sleep Apnea AD182, AD504, Placebo - Obstructive Sleep Apnea | Phase 2 | Completed | Apnimed | 15 | 2020-12-01 | 2022-09-02 |
| Combination Drug-Therapy for Patients With Untreated Obstructive Sleep Apnea Acetazolamide, Eszopiclone, Placebo - OSA, Obstructive Sleep Apnea | Phase 2 | Completed | University of California, San Diego | 20 | 2020-12-01 | 2024-05-29 |
| Crossover Trial of AD109 in Obstructive Sleep Apnea AD109, Atomoxetine, R-oxybutynin - Obstructive Sleep Apnea | Phase 2 | Completed | Apnimed | 60 | 2020-10-27 | 2023-01-31 |
| Medications for Obstructive Sleep Apnea In Children With Down Syndrome Atomoxetine and oxybutynin (ato-oxy) - Obstructive Sleep Apnea, Down Syndrome | Phase 2 | Completed | University of Arizona | 22 | 2020-10-21 | 2025-08-19 |
| Do Endotypes Predict Response and Sequelae in OSA Patients Eszopiclone, Supplemental Oxygen, Continuous Positive Airway Pressure (CPAP) - Obstructive Sleep Apnea, Sleep Apnea | Phase 2 | Completed | University of California, San Diego | 233 | 2020-08-01 | 2026-06-18 |
| Crossover Trial of AD036 in Obstructive Sleep Apnea AD036, Atomoxetine, Placebo - Obstructive Sleep Apnea | Phase 2 | Completed | Apnimed | 62 | 2020-07-15 | 2023-09-14 |
| Study of AD128 Versus Placebo in Obstructive Sleep Apnea AD128, Placebo - Obstructive Sleep Apnea | Phase 2 | Completed | Istituto Auxologico Italiano | 20 | 2020-07-03 | 2021-09-27 |
Showing 20 of 43. Sign in to see all of them.
Sleep Apnea, Obstructive (43) · Sleep Apnea Syndromes (14) · Hypertension (6) · Sleep Wake Disorders (4) · Apnea (2) · Cardiovascular Diseases (2) · Chronic Pain (2) · Obesity (2) · Pain (2) · Respiration Disorders (2) · Stroke (2) · Brain Ischemia (1) · Coronary Artery Disease (1) · Disorders of Excessive Somnolence (1) · Down Syndrome (1)
Dyssomnias (43) · Nervous System Diseases (43) · Respiratory Tract Diseases (43) · Sleep Disorders, Intrinsic (43) · Apnea (41) · Respiration Disorders (41) · Sleep Wake Disorders (39) · Sleep Apnea Syndromes (29) · Pathological Conditions, Signs and Symptoms (10) · Signs and Symptoms (10) · Neurologic Manifestations (8) · Vascular Diseases (7) · Cardiovascular Diseases (5) · Mental Disorders (5) · Signs and Symptoms, Respiratory (4)
Continuous Positive Airway Pressure (10) · Acetazolamide (6) · Atomoxetine Hydrochloride (5) · Eszopiclone (3) · Occlusal Splints (2) · (Lys-Gly)(5)cyclo(75-82)MBP(74-85) (1) · Adrenergic beta-Antagonists (1) · Bosentan (1) · Celecoxib (1) · Combined Modality Therapy (1) · Dimethyl Fumarate (1) · Dronabinol (1) · Fentanyl (1) · Hydromorphone (1) · Indomethacin (1)
Apnimed (8) · University of California, San Diego (6) · Brigham and Women's Hospital (5) · Apnex Medical, Inc. (2) · Göteborg University (2) · Johns Hopkins University (2) · Associação Fundo de Incentivo à Pesquisa (1) · Desitin Arzneimittel GmbH (1) · Duke University (1) · Hubei Hospital of Traditional Chinese Medicine (1) · Incannex Healthcare Ltd (1) · Istituto Auxologico Italiano (1) · Jazz Pharmaceuticals (1) · Mineralys Therapeutics Inc. (1) · Nykøbing Falster County Hospital (1)
United States (30) · Australia (2) · Sweden (2) · Belgium (1) · Brazil (1) · Canada (1) · China (1) · Denmark (1) · France (1) · Italy (1) · Netherlands (1)
Christopher Schmickl, MD, PhD (2) · Jan Hedner, MD. Prof. (2) · Jeremy Orr, MD (2) · Ron Farkas, MD (2) · Alan R Schwartz, M.D. (1) · Atul Malhotra, MD (1) · Beth Malow, M.D., M.S. (1) · Bradley A Edwards, PhD (1) · Bruce Corser, MD (1) · Carol Rosen, M.D. (1) · Christopher E Kline, MS (1) · Christopher N Schmickl, MD, PhD (1) · Christopher Schmickl (1) · Con Iber, MD (1) · Daniel Combs, MD (1)
PMID 18513353, PMID 18711110, PMID 21885958, PMID 22043118, PMID 22131599, PMID 22334806, PMID 22547887, PMID 22572632, PMID 22893765, PMID 22968110, PMID 24458967, PMID 24815497, PMID 24918372, PMID 25892349, PMID 26643404, PMID 29035093, PMID 29510792, PMID 29800466, PMID 32649638, PMID 34225174, PMID 34543665, PMID 35551600, PMID 35975547, PMID 36494591, PMID 36734173, PMID 36805833, PMID 37555595, PMID 37938917, PMID 38507976, PMID 38669011, PMID 39305436, PMID 39514000, PMID 39688178, PMID 40360261, PMID 40705710, PMID 41077049, PMID 41424523, PMID 41781273, PMID 41811641
K23HL151880 (2), 2009 (1), 2015 (1), 2019 (1), R01HL106410 (1), R01HL128658 (1), R01NS042698 (1), R03HL138068 (1), R61HL151254 (1), UL1RR024989 (1)